Miranda McKenzie

Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, PA / OCTOBER 21, 2026 / Geneos Therapeutics, a clinical stage biotherapeutics … Read more

Participants in early clinical trial had increased immune response, slowed tumor progression by Mark Reynolds May 12, 2026                                                                                 … Read more